Allay Therapeutics is a company.
Allay Therapeutics has raised $118.0M across 2 funding rounds.
Key people at Allay Therapeutics.
Allay Therapeutics has raised $118.0M in total across 2 funding rounds.
Allay Therapeutics is a clinical-stage biotechnology company developing ultra-sustained, non-opioid analgesic products to transform post-surgical pain management and patient recuperation.[1][2][3] Its proprietary platform combines validated local analgesics with biopolymers to create dissolvable implants that deliver targeted pain relief at the surgical site for weeks, an order of magnitude longer than current longest-lasting treatments, serving patients, surgeons, and healthcare systems burdened by opioid-related addiction, prolonged recovery, and high costs.[2][3][4] The company operates from the San Francisco Bay Area and Singapore, with recent milestones including FDA acceptance of its Investigational New Drug (IND) application for lead candidate ATX101 in October 2024 and a $57.5M Series D financing round to advance its pipeline.[3][8]
Allay Therapeutics emerged from The Foundry incubator and Lightstone Venture’s Singapore Fund, uniting a global team of entrepreneurs, scientists, clinicians, and innovators across San Francisco and Singapore to address stalled innovation in pain management.[2][3][5] While specific founding year and individual founders are not detailed in available sources, the company's platform was shaped by these incubators, focusing on non-opioid solutions amid the opioid crisis.[2][3] Early traction includes expansion of its clinical and scientific advisory boards in October 2024, FDA IND clearance for ATX101, and securing Series D funding from investors like Vertex Ventures HC and ClavystBio, signaling strong validation of its vision.[3][5][8]
Allay rides the wave of non-opioid innovation amid the global push to combat the opioid epidemic, which drives addiction, extended hospitalizations, and healthcare costs in post-surgical care.[1][3] Timing aligns with regulatory tailwinds like FDA fast-tracking non-addictive analgesics and Singapore's R&D ecosystem accelerating life sciences via investors like ClavystBio and Lightstone Ventures.[3][8] Market forces favoring Allay include surging demand for localized, long-acting therapies—evidenced by its Series D raise—and biotech trends in biopolymer drug delivery, positioning it to influence ecosystem shifts toward safer recovery tools and reduced systemic drug reliance.[2][4][8]
Allay is poised to advance ATX101 into clinical trials following FDA IND clearance, with its $57.5M Series D fueling pipeline expansion and global scaling from Singapore to worldwide markets.[3][8] Trends like AI-accelerated drug development (via advisors) and biopolymer advancements will shape its path, potentially disrupting a market dominated by short-acting or addictive options.[1][5] Its influence may grow by setting new standards for post-surgical care, enabling faster patient mobility and lower system costs, ultimately fulfilling its mission to end the era of inadequate pain management.[1][4]
Key people at Allay Therapeutics.
Allay Therapeutics has raised $118.0M in total across 2 funding rounds.
Allay Therapeutics's investors include Arboretum Ventures, Lightstone Ventures, New Enterprise Associates (NEA), Tak Cheung, New Enterprise Associates.
Allay Therapeutics has raised $118.0M across 2 funding rounds. Most recently, it raised $58.0M Series D in June 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2025 | $58.0M Series D | Arboretum Ventures, Lightstone Ventures, New Enterprise Associates (NEA), Tak Cheung, New Enterprise Associates | |
| Sep 1, 2021 | $60.0M Series C | Arboretum Ventures, Lightstone Ventures, New Enterprise Associates (NEA), Tak Cheung, New Enterprise Associates |
